ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia

Oncogene

Volumn 30, Issue 6, 2011, Pages 701-713

  Tonino, S H ^a   Van Laar, J ^a   Van Oers, M H ^a   Wang, J Y ^b   Eldering, E ^a   Kater, A P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

chemoresistance; CLL; Noxa; p53; platinumbased compounds; ROS

Indexed keywords

CASPASE; CD40 LIGAND; CISPLATIN; CYTARABINE; FLUDARABINE; MITOGEN ACTIVATED PROTEIN KINASE P38; OXALIPLATIN; PROTEIN NOXA; PROTEIN P73; PUMA PROTEIN; REACTIVE OXYGEN METABOLITE; RITUXIMAB;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CELL DEATH; CELL STRAIN HEK293; CHRONIC LYMPHATIC LEUKEMIA; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; LYMPH NODE; MAXIMUM PLASMA CONCENTRATION; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATION REDUCTION POTENTIAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ISOLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD40; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; TUMOR CELLS, CULTURED; UP-REGULATION; VIDARABINE;

ARA;

EID: 79951512093     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.441     Document Type: Article

References (51)

1. Akaboshi M, Kawai K, Ujeno Y, Takada S, Miyahara T. (1994). Binding characteristics of (-)-(R)-2-aminomethylpyrrolidine(1,1- cyclobutanedicarboxylato)-2-platin um(II) to DNA, RNA and protein molecules in HeLa cells and its lethal effect: comparison with cis- and trans- diamminedichloroplatinums(II). Jpn J Cancer Res 85: 106-111. (Pubitemid 24048298)
2. 3.H2O. J Inorg Biochem 99: 795-804. (Pubitemid 40247873)
3. Baou M, Kohlhaas SL, Butterworth M, Vogler M, Dinsdale D, Walewska R et al. (2010). Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica 95: 1510-1518.
4. Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L et al. (2009). PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res 15: 3354-3365.
5. Bouzar AB, Boxus M, Defoiche J, Berchem G, Macallan D, Pettengell R et al. (2009). Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 144: 41-52.
6. Brozovic A, Osmak M. (2007). Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 251: 1-16. (Pubitemid 46589761)
7. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393-403. (Pubitemid 40193310)
8. Clohessy JG, Zhuang J, Brady HJ. (2004). Characterisation of Mcl-1 cleavage during apoptosis of haematopoietic cells. Br J Haematol 125: 655-665. (Pubitemid 38747969)
9. Deriano L, Guipaud O, Merle-Beral H, Binet JL, Ricoul M, Potocki-Veronese G et al. (2005). Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. Blood 105: 4776-4783. (Pubitemid 40807303)
10. Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G et al. (2006). CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood 108: 3450-3457.
11. Flinterman M, Guelen L, Ezzati-Nik S, Killick R, Melino G, Tominaga K et al. (2005). E1A activates transcription of p73 and Noxa to induce apoptosis. J Biol Chem 280: 5945-5959. (Pubitemid 40280079)
12. Ford JM, Hanawalt PC. (1997). Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. J Biol Chem 272: 28073-28080. (Pubitemid 27473616)
13. Fruehauf JP, Meyskens Jr FL. (2007). Reactive oxygen species: a breath of life or death? Clin Cancer Res 13: 789-794. (Pubitemid 46340350)
14. Garrido N, Perez-Martos A, Faro M, Lou-Bonafonte JM, Fernandez-Silva P, Lopez-Perez MJ et al. (2008). Cisplatin-mediated impairment of mitochondrial DNA metabolism inversely correlates with glutathione levels. Biochem J 414: 93-102.
15. Geleziunas R, McQuillan A, Malapetsa A, Hutchinson M, Kopriva D, Wainberg MA et al. (1991). Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. J Natl Cancer Inst 83: 557-564.
16. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin Jr WG, Levrero M et al. (1999). The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399: 806-809. (Pubitemid 29293179)
17. Hagrman D, Goodisman J, Souid AK. (2004). Kinetic study on the reactions of platinum drugs with glutathione. J Pharmacol Exp Ther 308: 658-666. (Pubitemid 38134229)
18. Hallaert DY, Jaspers A, van Noesel CJ, Van Oers MH, Kater AP, Eldering E. (2008). c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 112: 5141-5149.
19. Husain K, Morris C, Whitworth C, Trammell GL, Rybak LP, Somani SM. (1998). Protection by ebselen against cisplatin-induced nephrotoxicity: antioxidant system. Mol Cell Biochem 178: 127-133. (Pubitemid 28121751)
20. Kater AP, Evers LM, Remmerswaal EB, Jaspers A, Oosterwijk MF, van Lier RA et al. (2004). CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 127: 404-415. (Pubitemid 39536592)
21. Kater AP, Tonino SH. (2010). Standards for the treatment of relapsed chronic lymphocytic leukemia: a case-based study. Clin Lymphoma Myeloma Leuk 10(Suppl 1): S34-S41.
22. Li L, Liu X, Glassman AB, Keating MJ, Stros M, Plunkett W et al. (1997). Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res 57: 1487-1494. (Pubitemid 27175565)
23. Mackus WJ, Kater AP, Grummels A, Evers LM, Hooijbrink B, Kramer MH et al. (2005). Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 19: 427-434. (Pubitemid 40403321)
24. Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS et al. (2004). The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 64: 2590-2600. (Pubitemid 38523917)
25. McCubrey JA, Lahair MM, Franklin RA. (2006). Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal 8: 1775-1789. (Pubitemid 44726351)
26. Miller CP, Rudra S, Keating MJ, Wierda WG, Palladino M, Chandra J. (2009). Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood 113: 4289-4299.
27. Monjanel-Mouterde S, Ciccolini J, Bagarry D, Zonta-David M, Duffaud F, Favre R et al. (2003). Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedback. J Clin Pharm Ther 28: 109-116. (Pubitemid 36566909)
28. Morales AA, Olsson A, Celsing F, Osterborg A, Jondal M, Osorio LM. (2005). High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int J Cancer 113: 730-737. (Pubitemid 40101253)
29. Moufarij MA, Sampath D, Keating MJ, Plunkett W. (2006). Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing inter-strand DNA crosslink removal. Blood 108: 4187-4193. (Pubitemid 44913291)
30. Mous R, Jaspers A, Luijks DM, Mellink CH, Van Oers MH, Kater AP et al. (2009). Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction. Leukemia 23: 1352-1355.
31. Munk Pedersen I, Reed J. (2004). Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 45: 2365-2372. (Pubitemid 40081179)
32. Nys K, Van Laethem A, Michiels C, Rubio N, Piette JG, Garmyn M et al. (2010). A p38(MAPK)/HIF-1pathway initiated by UVB irradiation is Required to induce Noxa and apoptosis of human keratinocytes. J Invest Dermatol 130: 2269-2276.
33. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T et al. (2000). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053-1058. (Pubitemid 30324238)
34. Oltra AM, Carbonell F, Tormos C, Iradi A, Saez GT. (2001). Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia. Free Radic Biol Med 30: 1286-1292. (Pubitemid 32463939)
35. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L et al. (2008). Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 112: 3807-3817.
36. Pettitt AR. (2003). Mechanism of action of purine analogues in chronic lymphocytic leukaemia. Br J Haematol 121: 692-702. (Pubitemid 36718185)
37. Rich T, Allen RL, Wyllie AH. (2000). Defying death after DNA damage. Nature 407: 777-783.
38. Rosato RR, Almenara JA, Maggio SC, Coe S, Atadja P, Dent P et al. (2008). Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileu-kemic interactions. Mol Cancer Ther 7: 3285-3297.
39. Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC et al. (2004). Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 104: 1428-1434. (Pubitemid 39166521)
40. Roue G, Lopez-Guerra M, Milpied P, Perez-Galan P, Villamor N, Montserrat E et al. (2008). Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 14: 6907-6915.
41. Seymour JF, Robertson LE, O'Brien S, Lerner S, Keating MJ. (1995). Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. Leuk Lymphoma 18: 493-496.
42. Smit LA, Hallaert DY, Spijker R, de Goeij B, Jaspers A, Kater AP et al. (2007). Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 109: 1660-1668. (Pubitemid 46242110)
43. Spitz DR, Phillips JW, Adams DT, Sherman CM, Deen DF, Li GC. (1993). Cellular resistance to oxidative stress is accompanied by resistance to cisplatin: the significance of increased catalase activity and total glutathione in hydrogen peroxide-resistant fibroblasts. J Cell Physiol 156: 72-79. (Pubitemid 23211264)
44. Tonino SH, van Gelder M, Eldering E, Van Oers MH, Kater AP. (2010). R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia. Leukemia 24: 652-654.
45. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y et al. (2008). Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 112: 1912-1922.
46. 0Brien S, Wen S et al. (2008). Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26: 196-203.
47. Van Bockstaele F, Verhasselt B, Philippe J. (2009). Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 23: 25-47.
48. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ et al. (2009). Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 113: 4403-4413.
49. Witte AB, Anestal K, Jerremalm E, Ehrsson H, Arner ES. (2005). Inhibition of thioredoxin reductase but not of gluta-thione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 39: 696-703. (Pubitemid 41112110)
50. Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A et al. (2008). Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112: 3322-3329.
51. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. (2003). Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101: 4098-4104. (Pubitemid 36857891)